Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > MonoSol Rx and Midatech Group Enter Collaboration Agreement to Unite Nanoparticle and Thin Film Drug Delivery Technologies

Abstract:
MonoSol Rx, the developers of PharmFilm(R) technology and a drug delivery company specializing in dissolving thin film pharmaceutical products, and Midatech Group Ltd, a world leader in the production and application of synthetically produced nanoparticles, announced today a partnership to develop new drug formulations combining biocompatible nanocells and PharmFilm delivery technologies.

MonoSol Rx and Midatech Group Enter Collaboration Agreement to Unite Nanoparticle and Thin Film Drug Delivery Technologies

WARREN, NJ and OXFORDSHIRE, England | Posted on November 3rd, 2008

Under terms of the agreement, MonoSol Rx and Midatech will jointly research, develop and commercialize new drug candidates designed to deliver therapeutic nanoparticles in thin film. Research and development will occur at MonoSol Rx's facility in Portage, Indiana and Midatech's facilities in Spain and Switzerland. Further terms were not disclosed.

A. Mark Schobel, president and CEO of MonoSol Rx, stated, "Our collaboration with Midatech provides us with an exciting entry into the emerging field of nanomedicine. The size and chemical composition of Midatech's biocompatible nanocells are ideally suited for delivery using our PharmFilm technology, and should provide another avenue for us to extend the commercial potential of new and currently marketed drugs. The combination of these two complementary and well-matched technologies offers a unique opportunity to move beyond the limitations of traditional delivery formulations to create new and compelling drug candidates with the potential for greater convenience, efficacy at lower doses, and faster onset of action. Most importantly, the mating of MonoSol Rx's and Midatech's technologies will enable the oral delivery of many challenging drugs that up to now could not be delivered orally."

Midatech's biocompatible nanocells possess a number of unique properties ideal for therapeutics, diagnostics and other enabling applications. Among the attributes, Midatech's nanocells are water soluble; can present multiple ligands, allowing for multivalent drug or multi-drug delivery on a single particle; and can be delivered via different routes of administration due to their size and stability to enzymatic digestion.

Professor Tom Rademacher, Chairman of Midatech Group, commented, "MonoSol Rx's PharmFilm technology provides an ideal platform for us to evaluate clinical applications for our biocompatible nanocell technology. PharmFilm's ability to carry highly uniform, accurate doses makes it well-suited to deliver our biocompatible nanocells sublingually, buccally or through traditional intragastric delivery. We look forward to working with MonoSol Rx to develop products with new methods of administration for existing drugs."

Keith J. Kendall, executive vice president and CFO of MonoSol Rx, stated, "Midatech's decision to partner with us is a testament to the strength and versatility of our PharmFilm technology platform. As partners, both MonoSol Rx and Midatech are well-positioned to develop and introduce the first thin film nanomedicines into the market."

####

About MonoSol Rx
MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm(R) technology to deliver drugs in quick dissolving films. PharmFilm(R) is designed to benefit patients by improving the convenience, efficacy, and compliance of currently marketed drugs. The Company is a leader in thin film drug delivery and has a strong intellectual property position, a portfolio of commercialized OTC drug products, and a pipeline of prescription formulations utilizing its PharmFilm(R) technology. With a vertically integrated development and production infrastructure, MonoSol Rx has the capacity to manufacture OTC drug products for near-term revenues that enable the funding of prescription product development programs that will generate long-term value.

The Company's commercialization strategy for all PharmFilm(R) products is to partner with the innovator or other specialty pharma or leading consumer products companies who have the core competency to sell-in and manage the sales and marketing of the products. For the Company's existing and future partners, PharmFilm(R) formulations represent revenue-life cycle extensions for products with patent lives that have expired or are approaching expiration. PharmFilm(R) is also a tool to help sales and marketing partners differentiate in competitive markets while offering unique advantages over drugs dosed by traditional tablets, capsules and ODTs.

Midatech Group Ltd is a world leader in the design, synthesis and manufacture of biocompatible nanoparticles. These nanoparticles can be used to create a wide variety of products with novel characteristics, functions and applications that have the potential for multiple diagnostic and therapeutic applications.

Created in 2000, Midatech has IP covering design, manufacture and application/use of nanoparticles in both diagnostic and therapeutic pharmaceutical areas. As well as in-house product development, it is prepared to licence this IP to 3rd Party pharmaceutical and diagnostic development partners whilst retaining manufacturing rights. Midatech has exclusive world-wide rights for technology relating to the synthesis and applications of self-assembling nanoparticles. The Company opened a cGMP standard design and manufacturing plant for nanocells -- Midatech Biogune -- in Bilbao, Spain in 2007.

For more information, please click here

Contacts:
MonoSol Rx:
Keith Kendall
Chief Financial Officer
(732) 564-5000
The Ruth Group (on behalf of MonoSol Rx)
Jason Rando (media)
646-536-7025

Stephanie Carrington / Sara Ephraim (investors)
646.536.7017/7002

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Virginia Tech physicists propose path to faster, more flexible robots: Virginia Tech physicists revealed a microscopic phenomenon that could greatly improve the performance of soft devices, such as agile flexible robots or microscopic capsules for drug delivery May 17th, 2024

Gene therapy relieves back pain, repairs damaged disc in mice: Study suggests nanocarriers loaded with DNA could replace opioids May 17th, 2024

Shedding light on perovskite hydrides using a new deposition technique: Researchers develop a methodology to grow single-crystal perovskite hydrides, enabling accurate hydride conductivity measurements May 17th, 2024

Oscillating paramagnetic Meissner effect and Berezinskii-Kosterlitz-Thouless transition in cuprate superconductor May 17th, 2024

Thin films

Utilizing palladium for addressing contact issues of buried oxide thin film transistors April 5th, 2024

Understanding the mechanism of non-uniform formation of diamond film on tools: Paving the way to a dry process with less environmental impact March 24th, 2023

New study introduces the best graphite films: The work by Distinguished Professor Feng Ding at UNIST has been published in the October 2022 issue of Nature Nanotechnology November 4th, 2022

Thin-film, high-frequency antenna array offers new flexibility for wireless communications November 5th, 2021

Nanomedicine

Virginia Tech physicists propose path to faster, more flexible robots: Virginia Tech physicists revealed a microscopic phenomenon that could greatly improve the performance of soft devices, such as agile flexible robots or microscopic capsules for drug delivery May 17th, 2024

Diamond glitter: A play of colors with artificial DNA crystals May 17th, 2024

Advances in priming B cell immunity against HIV pave the way to future HIV vaccines, shows quartet of new studies May 17th, 2024

New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024

Announcements

Virginia Tech physicists propose path to faster, more flexible robots: Virginia Tech physicists revealed a microscopic phenomenon that could greatly improve the performance of soft devices, such as agile flexible robots or microscopic capsules for drug delivery May 17th, 2024

Diamond glitter: A play of colors with artificial DNA crystals May 17th, 2024

Finding quantum order in chaos May 17th, 2024

Oscillating paramagnetic Meissner effect and Berezinskii-Kosterlitz-Thouless transition in cuprate superconductor May 17th, 2024

Alliances/Trade associations/Partnerships/Distributorships

Manchester graphene spin-out signs $1billion game-changing deal to help tackle global sustainability challenges: Landmark deal for the commercialisation of graphene April 14th, 2023

Chicago Quantum Exchange welcomes six new partners highlighting quantum technology solutions, from Chicago and beyond September 23rd, 2022

CEA & Partners Present ‘Powerful Step Towards Industrialization’ Of Linear Si Quantum Dot Arrays Using FDSOI Material at VLSI Symposium: Invited paper reports 3-step characterization chain and resulting methodologies and metrics that accelerate learning, provide data on device pe June 17th, 2022

University of Illinois Chicago joins Brookhaven Lab's Quantum Center June 10th, 2022

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project